VANI (Vivani Medical, Inc. Common Stock (DE))
Insider Trading Activity
Every open-market purchase and sale reported by VANI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-30 | Truc Le | Chief Operations Officer | A | — | — |
| 2026-07-30 | Adam Mendelsohn | Chief Executive Officer | A | — | — |
| 2026-07-30 | Donald Dwyer | Chief Business Officer | A | — | — |
| 2026-07-30 | Lisa Ellen Porter | Chief Medical Officer | A | — | — |
| 2026-07-30 | Anthony Baldor | Chief Financial Officer | A | — | — |
| 2026-07-28 | DANIEL BRADBURY | Director | A | — | — |
| 2026-07-16 | Gregg Williams | Director | Buy | — | — |
| 2026-06-26 | August J Moretti | Director | A | — | — |
| 2026-06-25 | Aaron Mendelsohn | Director | A | — | — |
| 2026-06-25 | Alexandra L. Popoff | Director | A | — | — |
| 2026-06-25 | DANIEL BRADBURY | Director | A | — | — |
| 2026-06-25 | Gregg Williams | Director | A | — | — |
| 2026-06-16 | Gregg Williams | Director | Buy | — | — |
| 2026-05-19 | Gregg Williams | Director | Buy | — | — |
| 2026-04-16 | Gregg Williams | Director | Buy | — | — |
| 2026-03-16 | Gregg Williams | Director | Buy | — | — |
| 2026-02-17 | Gregg Williams | Director | Buy | — | — |
| 2026-01-28 | Gregg Williams | Director | Buy | — | — |
| 2026-01-20 | Gregg Williams | Director | Buy | — | — |
| 2026-01-05 | Gregg Williams | Director | A | — | — |
| 2026-01-05 | DANIEL BRADBURY | Director | A | — | — |
| 2025-12-31 | Aaron Mendelsohn | Director | MIXED | — | — |
| 2025-12-16 | Gregg Williams | Director | Buy | — | — |
| 2025-11-17 | Gregg Williams | Director | Buy | — | — |
| 2025-10-28 | Gregg Williams | Director | Buy | — | — |
| 2025-10-16 | Gregg Williams | Director | Buy | — | — |
| 2025-09-17 | Gregg Williams | Director | Buy | — | — |
| 2025-06-26 | Wilford Dean Baker | Director | A | — | — |
| 2025-06-26 | Gregg Williams | Director | MIXED | — | — |
| 2025-06-26 | Alexandra L. Popoff | Director | A | — | — |
| 2025-06-26 | Aaron Mendelsohn | Director | A | — | — |
| 2025-06-26 | DANIEL BRADBURY | Director | MIXED | — | — |
| 2025-06-17 | Anthony Baldor | Chief Financial Officer | A | — | — |
| 2025-05-16 | Gregg Williams | Director | Buy | — | — |
| 2025-05-14 | Lisa Ellen Porter | Chief Medical Officer | A | — | — |
| 2025-05-14 | Adam Mendelsohn | Chief Executive Officer | A | — | — |
| 2025-05-14 | Donald Dwyer | Chief Business Officer | A | — | — |
| 2025-05-14 | Brigid Makes | Chief Financial Officer | A | — | — |
| 2025-05-14 | Truc Le | Chief Operations Officer | A | — | — |
| 2025-04-28 | Gregg Williams | Director | Buy | — | — |
| 2025-04-23 | Gregg Williams | Director | Buy | — | — |
| 2025-04-11 | Gregg Williams | Director | Buy | — | — |
| 2025-04-08 | Gregg Williams | Director | Buy | — | — |
| 2025-04-04 | Gregg Williams | Director | Buy | — | — |
| 2025-04-01 | Donald Dwyer | Chief Business Officer | Buy | — | — |
| 2025-03-03 | Donald Dwyer | Chief Business Officer | Buy | — | — |
| 2025-01-03 | DANIEL BRADBURY | Director | A | — | — |
| 2025-01-03 | Gregg Williams | Director | A | — | — |
| 2024-11-13 | Gregg Williams | Director | Buy | — | — |
| 2024-10-03 | Donald Dwyer | Chief Business Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 41,711,936 | — |
| — | Chief Executive Officer | 3,605,015 | — |
| — | 10%+ Owner | 3,012,894 | — |
| — | Director | 1,086,487 | — |
| — | Chief Business Officer | 55,000 | — |
| — | Chief Financial Officer | 15,000 | — |
| — | Director | 199 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VANI quote page; the site-wide leaderboard is on the insider transactions hub.